Fred E Cooperrider

Array ( [id] => 9865229 [patent_doc_number] => 20150045248 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-02-12 [patent_title] => 'METHOD FOR IDENTIFYING DISEASE ASSOCIATED WITH ABUNDANCE OF TDP-43 IN CELL' [patent_app_type] => utility [patent_app_number] => 14/380555 [patent_app_country] => US [patent_app_date] => 2013-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 25 [patent_no_of_words] => 25214 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14380555 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8892315 [patent_doc_number] => 20130165499 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-06-27 [patent_title] => 'Methods And Compositions For Prevention Or Treatment Of RSV Infection' [patent_app_type] => utility [patent_app_number] => 13/778614 [patent_app_country] => US [patent_app_date] => 2013-02-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 46 [patent_figures_cnt] => 46 [patent_no_of_words] => 35186 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13778614 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9685304 [patent_doc_number] => 20140242069 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-08-28 [patent_title] => 'KRT19 Stabilizing HER2 and Use thereof' [patent_app_type] => utility [patent_app_number] => 13/777501 [patent_app_country] => US [patent_app_date] => 2013-02-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 27 [patent_no_of_words] => 12661 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13777501 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8939469 [patent_doc_number] => 20130189267 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-07-25 [patent_title] => 'MEANS AND METHODS FOR TREATING OR PREVENTING BRAIN TUMORS BASED ON THE NUCLEAR RECEPTOR TAILLESS (TIX)' [patent_app_type] => utility [patent_app_number] => 13/774359 [patent_app_country] => US [patent_app_date] => 2013-02-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 5317 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13774359 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9331178 [patent_doc_number] => 20140057960 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-02-27 [patent_title] => 'NOVEL REPRESSOR ON IFN-LAMBDA PROMOTER AND SIRNA AGAINST ZEB1 AND BLIMP-1 TO INCREASE IFN-LAMBDA GENE ACTIVITY' [patent_app_type] => utility [patent_app_number] => 13/771855 [patent_app_country] => US [patent_app_date] => 2013-02-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 39 [patent_figures_cnt] => 39 [patent_no_of_words] => 22614 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13771855 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9888769 [patent_doc_number] => 08975023 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-03-10 [patent_title] => 'Method for controlling the amount of gene product, and agent for controlling the amount of gene product' [patent_app_type] => utility [patent_app_number] => 13/770682 [patent_app_country] => US [patent_app_date] => 2013-02-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 15 [patent_no_of_words] => 11226 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 173 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13770682 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10678350 [patent_doc_number] => 20160024495 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-01-28 [patent_title] => 'LNA ANTISENSE OLIGONUCLEOTIDES FOR THE MODULATION OF MYC EXPRESSION' [patent_app_type] => utility [patent_app_number] => 14/378698 [patent_app_country] => US [patent_app_date] => 2013-02-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 18724 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14378698 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9330064 [patent_doc_number] => 20140056846 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-02-27 [patent_title] => 'Treating Hepatitis C Virus Infection' [patent_app_type] => utility [patent_app_number] => 13/765506 [patent_app_country] => US [patent_app_date] => 2013-02-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3230 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13765506 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9983630 [patent_doc_number] => 09029339 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-05-12 [patent_title] => 'Impaired wound healing compositions and methods' [patent_app_type] => utility [patent_app_number] => 13/764674 [patent_app_country] => US [patent_app_date] => 2013-02-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 22048 [patent_no_of_claims] => 53 [patent_no_of_ind_claims] => 11 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13764674 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9635519 [patent_doc_number] => 20140213628 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-07-31 [patent_title] => 'COMPOSITIONS AND METHODS FOR THE TREATMENT OF SEPSIS AND OTHER DISORDERS INVOLVING PHOSPHOLIPASE A2 INDUCTION' [patent_app_type] => utility [patent_app_number] => 13/756449 [patent_app_country] => US [patent_app_date] => 2013-01-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 21612 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13756449 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11191756 [patent_doc_number] => 09422561 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-08-23 [patent_title] => 'Treatment of disease by modulation of SIRT6' [patent_app_type] => utility [patent_app_number] => 14/374229 [patent_app_country] => US [patent_app_date] => 2013-01-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 15 [patent_no_of_words] => 5913 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 115 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14374229 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8828584 [patent_doc_number] => 20130129629 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-05-23 [patent_title] => 'MODULATION OF BCL11A FOR TREATMENT OF HEMOGLOBINOPATHIES' [patent_app_type] => utility [patent_app_number] => 13/743399 [patent_app_country] => US [patent_app_date] => 2013-01-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 18 [patent_no_of_words] => 25392 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13743399 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8830107 [patent_doc_number] => 20130131149 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-05-23 [patent_title] => 'METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF ANDROGEN RECEPTOR BY DOUBLE-STRANDED RNA' [patent_app_type] => utility [patent_app_number] => 13/723623 [patent_app_country] => US [patent_app_date] => 2012-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 45 [patent_figures_cnt] => 45 [patent_no_of_words] => 138722 [patent_no_of_claims] => 43 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13723623 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10968263 [patent_doc_number] => 20140371296 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-12-18 [patent_title] => 'METHODS FOR MODULATING METASTASIS-ASSOCIATED-IN-LUNG-ADENOCARCINOMA-TRANSCRIPT-1 (MALAT-1) EXPRESSION' [patent_app_type] => utility [patent_app_number] => 14/368269 [patent_app_country] => US [patent_app_date] => 2012-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27121 [patent_no_of_claims] => 81 [patent_no_of_ind_claims] => 42 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14368269 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9844266 [patent_doc_number] => 08946183 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-02-03 [patent_title] => 'Compositions and methods for modulation of SMN2 splicing' [patent_app_type] => utility [patent_app_number] => 13/720474 [patent_app_country] => US [patent_app_date] => 2012-12-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13456 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 48 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13720474 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10920689 [patent_doc_number] => 20140323709 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-10-30 [patent_title] => 'OLIGONUCLEOTIDE AND THERAPEUTIC AGENT FOR HYPERLIPIDEMIA CONTAINING SAME AS ACTIVE INGREDIENT' [patent_app_type] => utility [patent_app_number] => 14/363315 [patent_app_country] => US [patent_app_date] => 2012-12-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 10570 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14363315 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11828981 [patent_doc_number] => 09725716 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-08-08 [patent_title] => 'Non-ionic, low osmolar contrast agents for delivery of antisense oligonucleotides and treatment of disease' [patent_app_type] => utility [patent_app_number] => 14/363670 [patent_app_country] => US [patent_app_date] => 2012-12-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 10 [patent_no_of_words] => 18219 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14363670 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9648637 [patent_doc_number] => 08802648 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-08-12 [patent_title] => 'Repressor on IFN-λ promoter and siRNA against ZEB1 and BLIMP-1 to increase IFN-λ gene activity' [patent_app_type] => utility [patent_app_number] => 13/693383 [patent_app_country] => US [patent_app_date] => 2012-12-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 28 [patent_no_of_words] => 16314 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 60 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13693383 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10162537 [patent_doc_number] => 09193754 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-11-24 [patent_title] => 'Formulations comprising antisense nucleotides to connexins' [patent_app_type] => utility [patent_app_number] => 13/681383 [patent_app_country] => US [patent_app_date] => 2012-11-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 19 [patent_no_of_words] => 11676 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13681383 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8830286 [patent_doc_number] => 20130131331 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-05-23 [patent_title] => 'CANCER-CELL-SPECIFIC CYTOSTATIC AGENT' [patent_app_type] => utility [patent_app_number] => 13/671118 [patent_app_country] => US [patent_app_date] => 2012-11-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 6855 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13671118 [rel_patent_id] =>[rel_patent_doc_number] =>)